Lynn L. Silver
Lynn L. Silver
President, LL Silver Consulting, LLC
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
E Tacconelli, E Carrara, et al.
The Lancet Infectious Diseases, 2017
Challenges of antibacterial discovery
LL Silver
Clinical microbiology reviews 24 (1), 71-109, 2011
Platensimycin is a selective FabF inhibitor with potent antibiotic properties
J Wang, SM Soisson, K Young, W Shoop, S Kodali, A Galgoci, R Painter, ...
Nature 441 (7091), 358-361, 2006
Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center
N Woodford, PM Tierno Jr, K Young, L Tysall, MFI Palepou, E Ward, ...
Antimicrobial agents and chemotherapy 48 (12), 4793-4799, 2004
Antibacterial agents that inhibit lipid A biosynthesis
HR Onishi, BA Pelak, LS Gerckens, LL Silver, FM Kahan, MH Chen, ...
Science 274 (5289), 980-982, 1996
Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala
M Ge, Z Chen, H Russell, J Kohler, LL Silver, R Kerns, S Fukuzawa, ...
Science 284 (5413), 507-511, 1999
Discovery and development of new antibiotics: the problem of antibiotic resistance.
LL Silver, KA Bostian
Antimicrobial agents and chemotherapy 37 (3), 377, 1993
Multi-targeting by monotherapeutic antibacterials
LL Silver
Nature Reviews Drug Discovery 6 (1), 41-55, 2007
Discovery of FabH/FabF inhibitors from natural products
K Young, H Jayasuriya, JG Ondeyka, K Herath, C Zhang, S Kodali, ...
Antimicrobial agents and chemotherapy 50 (2), 519-526, 2006
Bacteriophage T4 gene 41 protein, required for the synthesis of RNA primers, is also a DNA helicase.
M Venkatesan, LL Silver, NG Nossal
Journal of Biological Chemistry 257 (20), 12426-12434, 1982
The envA permeability/cell division gene of Escherichia coli encodes the second enzyme of lipid A biosynthesis
K Young, LL Silver, D Bramhill, P Cameron, SS Eveland, CRH Raetz, ...
Journal of Biological Chemistry 270 (51), 30384-30391, 1995
Determination of selectivity and efficacy of fatty acid synthesis inhibitors
S Kodali, A Galgoci, K Young, R Painter, LL Silver, KB Herath, SB Singh, ...
Journal of Biological Chemistry 280 (2), 1669-1677, 2005
Fosfomycin: mechanism and resistance
LL Silver
Cold Spring Harbor perspectives in medicine 7 (2), a025262, 2017
Novel inhibitors of bacterial cell wall synthesis
LL Silver
Current opinion in microbiology 6 (5), 431-438, 2003
Screening of natural products for antimicrobial agents
L Silver, K Bostian
European Journal of Clinical Microbiology & Infectious Diseases 9 (7), 455-461, 1990
What is an “ideal” antibiotic? Discovery challenges and path forward
SB Singh, K Young, LL Silver
Biochemical pharmacology 133, 63-73, 2017
In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase-and extended-spectrum β-lactamase-producing Klebsiella …
J Kohler, KL Dorso, K Young, GG Hammond, H Rosen, H Kropp, LL Silver
Antimicrobial agents and chemotherapy 43 (5), 1170-1176, 1999
The Role of Hydrophobic Substituents in the Biological Activity of Glycopeptide Antibiotics
R Kerns, SD Dong, S Fukuzawa, J Carbeck, J Kohler, L Silver, D Kahne
JOURNAL-AMERICAN CHEMICAL SOCIETY 122 (50), 12608-12609, 2000
Does the cell wall of bacteria remain a viable source of targets for novel antibiotics?
LL Silver
Biochemical pharmacology 71 (7), 996-1005, 2006
A Gestalt approach to Gram-negative entry
LL Silver
Bioorganic & medicinal chemistry 24 (24), 6379-6389, 2016
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20